Podium to Practice: ESMO® 2026 – GU: LITESPARK-012
OR
Studies / Trials Discussed
3586O – First-line pembrolizumab + lenvatinib + belzutifan or MK-1308A + lenvatinib in advanced RCC: randomized open-label phase 3 LITESPARK-012 study
Speakers
Explore more from your favourite experts – click their name to access their entire library of content.
Studies/trials discussed:
3586O – First-line pembrolizumab + lenvatinib + belzutifan or MK-1308A + lenvatinib in advanced RCC: randomized open-label phase 3 LITESPARK-012 study
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.